Roche granted FDA review for novel breast cancer therapy
Source: SeekingAlpha
2026-02-20 08:54:31 ET
More on Roche
- Roche Holding AG (RHHBY) Shareholder/Analyst Presentation
- Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
- Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
- Oakmark Global Concentrated Strategy adds SNY; exits MBGAF and RHHBY
- Genentech's Gazyva succeeds in phase 3 trial for primary membranous nephropathy
Read the full article on Seeking Alpha
For further details see:
Roche granted FDA review for novel breast cancer therapy
Roche Holding Ltd
NASDAQ: RHHBF
RHHBF Trading
-6.23% G/L:
$436.044 Last:
31 Volume:
$411.36 Open:
RHHBF Latest News
RHHBF Stock Data
$362,551,633,888
800,578,845
N/A
474
N/A
Pharmaceuticals
Healthcare
CH
Basel Switzerland
